Core Points - TILT Holdings Inc. announced that the Supreme Court of British Columbia granted an order for a meeting of noteholders to vote on a proposed Plan of Arrangement on December 1, 2025 [1] - If the Plan is approved by the required majority, TILT intends to seek court sanctioning of the Plan on December 5, 2025 [1] Company Overview - TILT Holdings Inc. is a global provider of cannabis business solutions, including inhalation technologies, cultivation, manufacturing, processing, brand development, and retail [2] - The company operates a diverse portfolio, including Jupiter Research LLC, which focuses on vaporization technology and recently received EU medical device certification for a handheld liquid inhalation device [2] - TILT also operates Commonwealth Alternative Care, Inc. in Massachusetts and Standard Farms Ohio, LLC in Ohio, and holds a permit for Standard Farms LLC in Pennsylvania [2] Future Plans - The company is focused on restructuring and optimizing its business strategy, including potential reductions in corporate overhead and headcount [3][4] - TILT aims to strengthen its balance sheet and enhance shareholder value through its ongoing business optimization strategy [3][4]

SCOTTSDALE Ariz., Nov. 14, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. ("TILT" or the "Company") (Cboe CA: TILT) (OTCID: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced that, following its announcement on November 7, 2025 that the Supreme Court of British Columbia had issued an initial order granting the Company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. ...

Core Points - TILT Holdings Inc. announced that trading in its securities was suspended following an initial order from the Supreme Court of British Columbia granting the company protection under the Companies' Creditors Arrangement Act [1][2] - The company's common shares will be officially delisted as of November 18, 2025, with no assurance that the suspension will be lifted prior to this date [3] Company Overview - TILT is a global provider of cannabis business solutions, including inhalation technologies, cultivation, manufacturing, processing, brand development, and retail [1] - The company's core business is Jupiter Research LLC, a leader in the vaporization segment, which recently received EU medical device certification for a handheld liquid inhalation device [4] - TILT operates in North America, South America, Israel, and the European Union, with additional operations in Massachusetts and Ohio [4]

SCOTTSDALE, Ariz., Nov. 07, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCID: TLLTF), a global provider of cannabis business solutions including inhalation technologies, cultivation, manufacturing, processing, brand development and retail, announced it has reached agreement with the holders (the “Noteholders”) of senior secured notes of the Company (the “Senior Notes”), and that the Supreme Court of British Columbia (the “Court”) has issued an initial order (“Init ...

Core Viewpoint - TILT Holdings Inc. is undergoing a strategic transformation to become a focused, asset-light business centered on its Jupiter platform, with key milestones achieved in regulatory approvals and management agreements, while also planning to exit plant-touching operations in Ohio and Massachusetts [2][3]. Financial Summary - Revenue from continuing operations, excluding Ohio and Massachusetts, was $10.5 million for Q2 2025, down from $19.0 million in the prior year, primarily due to lower revenue from the Jupiter segment and macroeconomic pressures [4]. - Gross profit from continuing operations was $1.8 million, with a gross margin of 17.4%, compared to $3.6 million and 18.9% in the prior year, reflecting price compression and a shift in product mix [4]. - Net loss from continuing operations was $9.2 million, an improvement from a net loss of $16.6 million in the prior year, driven by decreased income tax expense and operating expenses [4]. - Adjusted EBITDA from continuing operations was $(2.0) million, compared to $(1.2) million in Q2 2024, attributed to lower gross profit [4]. - Cash flow from continuing operations was $4.4 million for the period, compared to $2.1 million cash used in the same period last year [4]. Operational Highlights - The company received regulatory approval for a retail transaction in Massachusetts and entered a management services agreement with MariMed for Standard Farms Pennsylvania [9]. - TILT achieved EU MDR certification for its QMID™ handheld vaporizer, positioning it for expansion in global medical markets [9]. - New product SKUs were soft-launched to broaden the product portfolio and meet customer needs [9]. - The company received a $3.5 million refund related to the Employee Retention Credit from the IRS [9]. Strategic Focus - The planned exit from U.S. plant-touching operations in Massachusetts and Ohio is a significant strategic shift, qualifying these assets for reporting as discontinued operations [3]. - The transition to a commission-based model for certain customers is part of the strategy to simplify operations and improve capital efficiency [2][4]. Cash Position - As of June 30, 2025, the company had $2.0 million in cash and cash equivalents, down from $2.9 million at the end of 2024 [4].

PHOENIX, June 18, 2025 (GLOBE NEWSWIRE) -- TILT Holdings Inc. (“TILT” or the “Company”) (Cboe CA: TILT) (OTCPK: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, today announces the results of the 2025 annual general meeting of shareholders of TILT (the “Shareholders”) held virtually on Tuesday, June 17, 2025 (the “Meeting”). The Company put forward the following proposals to be voted on by the ...